These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 15743507

  • 1. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F.
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [Abstract] [Full Text] [Related]

  • 2. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY.
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [Abstract] [Full Text] [Related]

  • 3. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 Mar; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 4. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R.
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [Abstract] [Full Text] [Related]

  • 5. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
    Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D.
    Clin Cancer Res; 2005 Jun 15; 11(12):4393-9. PubMed ID: 15958623
    [Abstract] [Full Text] [Related]

  • 6. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE, Wallis T, Tabasczka P, Visscher DW.
    Mod Pathol; 2000 Jan 15; 13(1):37-45. PubMed ID: 10658908
    [Abstract] [Full Text] [Related]

  • 7. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.
    Merola R, Mottolese M, Orlandi G, Vico E, Cognetti F, Sperduti I, Fabi A, Vitelli G, Cianciulli AM.
    Eur J Cancer; 2006 Jul 15; 42(10):1501-6. PubMed ID: 16762541
    [Abstract] [Full Text] [Related]

  • 8. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS, Wang Y, Tull J, Zhang S.
    Diagn Mol Pathol; 2009 Mar 15; 18(1):30-3. PubMed ID: 19214111
    [Abstract] [Full Text] [Related]

  • 9. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct 15; 35(10):584-8. PubMed ID: 17134563
    [Abstract] [Full Text] [Related]

  • 10. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L.
    Int J Surg Pathol; 2009 Jun 15; 17(3):198-205. PubMed ID: 19443884
    [Abstract] [Full Text] [Related]

  • 11. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J.
    Am J Clin Pathol; 2002 Jun 15; 117(6):935-43. PubMed ID: 12047146
    [Abstract] [Full Text] [Related]

  • 12. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.
    Mod Pathol; 2000 Nov 15; 13(11):1238-43. PubMed ID: 11106082
    [Abstract] [Full Text] [Related]

  • 13. Genetic alterations in ERBB2-amplified breast carcinomas.
    Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung BM, Waldman FM.
    Clin Cancer Res; 1999 Dec 15; 5(12):4140-5. PubMed ID: 10632352
    [Abstract] [Full Text] [Related]

  • 14. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S.
    Gynecol Oncol; 2005 Jul 15; 98(1):24-30. PubMed ID: 15894362
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 15; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 16. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.
    Pol J Pathol; 2004 Oct 15; 55(4):165-71. PubMed ID: 15757204
    [Abstract] [Full Text] [Related]

  • 17. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.
    Mod Pathol; 2002 Jun 15; 15(6):657-65. PubMed ID: 12065780
    [Abstract] [Full Text] [Related]

  • 18. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C.
    Histopathology; 2005 Apr 15; 46(4):431-41. PubMed ID: 15810955
    [Abstract] [Full Text] [Related]

  • 19. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB, de Weger RA, van Diest PJ.
    Breast Cancer Res Treat; 2010 Feb 15; 120(1):1-7. PubMed ID: 19760503
    [Abstract] [Full Text] [Related]

  • 20. c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast.
    Selim AG, El-Ayat G, Wells CA.
    J Pathol; 2000 Jun 15; 191(2):138-42. PubMed ID: 10861572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.